Metabolic study in mice could lead to 'good cholesterol' boosters

Researchers have identified a new player in the control of so-called “good” cholesterol that circulates in the bloodstream and reduces heart attack risk, according to a report in the August issue of Cell Metabolism, a publication of Cell Press.

Should the metabolic pathway uncovered in mice operate similarly in humans, the new discovery could point the way to therapies that protect against heart disease by boosting concentrations of the beneficial high-density lipoprotein cholesterol (HDL-C).

“By and large, the medicines now available lower levels of the ‘bad’ low-density lipoprotein cholesterol [LDL-C],” said Weijun Jin of the University of Pennsylvania School of Medicine. “There is a great need for methods to raise good cholesterol levels. Our findings suggest there may be multiple places to interrupt the metabolism of HDL-C.”

LDL-C can build up in blood vessel walls, increasing the risk of heart disease or stroke. By contrast, HDL-C tends to carry cholesterol away from the arteries to the liver—a process known as reverse cholesterol transport—where it is broken down and then eliminated from the body.

Existing LDL-C-lowering drugs such as statins can reduce the risk of heart attack by 20 to 35 percent, Jin said. However, treatment methods that would simultaneously lower bad cholesterol and increase good cholesterol have the potential to work even better. Indeed, researchers believe that increasing HDL-C while lowering LDL-C might cut heart attack risk by as much as 70 percent, he explained.

In the current study, the researchers found that treatments that partially block the activity of liver enzymes called proprotein convertases decreased plasma HDL-C levels in mice. They showed that the metabolic effect of the proprotein convertases depended on yet another factor, an enzyme called endothelial lipase (EL), which breaks down HDL-C. Proprotein convertases normally reduce EL function, they reported. Thus, the loss of proprotein convertase activity leads to an increase in EL and a decline in HDL-C.

Likewise, they showed that increased activity of proprotein convertases in the liver gives a significant boost to the protective HDL-C.

“Proprotein convertases are an unexpected new player in HDL-C metabolism,” Jin said. “By manipulating levels of the enzyme in both directions, we were able to reduce HDL-C to almost nothing or double it.” That wide range of effects suggests that it may be “theoretically possible to manipulate good cholesterol levels to whatever point you like.”

He emphasized, however, that the new findings represent basic research in animals. Further investigation will examine to what extent the pathway is preserved in humans, Jin said. The authors will also look for chemicals capable of modifying the pathway, which could hold promise as new good-cholesterol-boosting drugs.

Source: Cell Press

Related stories:

Cholesterol drugs lower risk of stroke for elderly too
Elderly people who take a cholesterol drug after a stroke or mini-stroke lower their risk of having another stroke just as much as younger people in the same situation, according to research published in the September 3, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.
At risk for peripheral arterial disease? Simple quiz provides key so you can circulate better
Ten million Americans have peripheral arterial disease (PAD), and research shows that the highest risk populations include African-Americans (twice as likely to develop clogged leg arteries), seniors (12-20 percent develop PAD) and diabetics (one in three who are over the age of 50 develop PAD). Legs for Life®—a community health and public information program—recommends that older Americans take its free, online self-assessment quiz.
Smoking riskier to women's hearts than men's
(AP) -- Women typically get heart disease much later than men, but not if they smoke, researchers said Tuesday. In fact, women who smoke have heart attacks nearly 14 years earlier than women who don't smoke, Norwegian doctors reported in a study presented to the European Society of Cardiology. For men, the gap is not so dramatic; male smokers have heart attacks about six years earlier than men who don't smoke.
Pfizer resuming ads for Lipitor after controversy
(AP) -- Television ads for the world's top-selling drug, cholesterol fighter Lipitor, are back, six months after Pfizer Inc. pulled them amid charges its use of a celebrity doctor endorser who's never practiced medicine misled the public. This time, Pfizer is leaving out the celebrity.
Millions face undiagnosed heart risk say researchers after mass screening
One in three people with a high risk of developing cardiovascular disease (CVD) over the next 10 years have not been diagnosed, according to a major UK study in the September issue of IJCP, the International Journal of Clinical Practice.
Doctors say Vytorin-cancer link can't be ruled out
(AP) -- Results from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with great caution until more is known, editors of a leading medical journal urged Tuesday.
Watch out for drug names that look, sound alike
(AP) -- Take the generic drug clonidine for high blood pressure? Double-check that you didn't leave the drugstore with Klonopin for seizures, or the gout medicine colchicine.
Sex hormones link to heart risk
Men are more prone to – and likely to die of - heart disease compared with women of a similar age – and sex hormones are to blame, according to a new University of Leicester led study.

News discussion:

Medicine & Health news